A highly effective and inexpensive standardized treatment of multidrug-resistant tuberculosis: a multicenter prospective study in China

A highly effective and inexpensive standardized treatment of multidrug-resistant tuberculosis: a multicenter prospective study in China

Abstract Background To verify the efficacy and safety of an inexpensive standardized regimen for multidrug-resistant tuberculosis (MDR-TB) with low resistance to isoniazid (INH), a multicenter prospective study was conducted in eastern China. Methods Patients diagnosed as MDR-TB with low concentrati...

Full description

Bibliographic Details
Main Authors:	Wenwen Sun, Zheyuan Wu, Ying Zhou, Fan Xia, Qin Tang, Jie Wang, Jinghui Yang, Fangyou Yu, Hua Yang, Heping Xiao, Lin Fan
Format:	Article
Language:	English
Published:	BMC 2021-08-01
Series:	BMC Infectious Diseases
Subjects:	MDR-TB Treatment regimen MIC Treatment outcome Adverse effects
Online Access:	https://doi.org/10.1186/s12879-021-06553-2

Similar Items

Applicability of the shorter ‘Bangladesh regimen’ in high multidrug-resistant tuberculosis settings
by: Giovanni Sotgiu, et al.
Published: (2017-03-01)

Comparative effectiveness of individualized longer and standardized shorter regimens in the treatment of multidrug resistant tuberculosis in a high burden country
by: Abdul Wahid, et al.
Published: (2022-09-01)

Update of drug-resistant tuberculosis treatment guidelines: A turning point
by: Elisa Vanino, et al.
Published: (2023-05-01)

The Correlations of Minimal Inhibitory Concentration Values of Anti-TB Drugs with Treatment Outcomes and Clinical Profiles in Patients with Multidrug-Resistant Tuberculosis (MDR-TB) in China
by: Tang Q, et al.
Published: (2022-09-01)

Treatment outcomes of multidrug-resistant tuberculosis patients receiving ambulatory treatment in Shenzhen, China: a retrospective cohort study
by: Ji Lecai, et al.
Published: (2023-06-01)

Factors Associated with Medical Follow-Up Adherence for Patients on All-Oral Regimen for Multidrug-Resistant Tuberculosis in Shenzhen, China
by: Li H, et al.
Published: (2021-07-01)

Off-Label Use of Bedaquiline in Children and Adolescents with Multidrug-Resistant Tuberculosis
by: Jay Achar, et al.
Published: (2017-10-01)

Current treatment of multidrug resistant tuberculosis in Ethiopia: an aggregated and individual patients’ data analysis for outcome and effectiveness of the current regimens
by: Setegn Eshetie, et al.
Published: (2018-09-01)

Management of multidrug resistant tuberculosis (MDR-TB) – Monitoring is the key to successful
by: J.S. Akshata, et al.
Published: (2016-04-01)

Effectiveness and safety of fully oral modified shorter treatment regimen for multidrug-resistant tuberculosis in Georgia, 2019-2020
by: Teona Avaliani, et al.
Published: (2021-01-01)

Factors associated with multidrug-resistant tuberculosis
by: Md Nurul Amin, et al.
Published: (2009-01-01)

Few eligible for the newly recommended short course MDR-TB regimen at a large Mumbai private clinic
by: Zarir F. Udwadia, et al.
Published: (2019-01-01)

Epidemiology of multidrug-resistant tuberculosis (MDR-TB) in Ethiopia: a systematic review and meta-analysis of the prevalence, determinants and treatment outcome
by: Tadele Girum, et al.
Published: (2018-06-01)

Risk factors for the occurrence of multidrug-resistant tuberculosis among patients undergoing multidrug-resistant tuberculosis treatment in East Shoa, Ethiopia
by: Fanta Desissa, et al.
Published: (2018-04-01)

The efficacy and safety of high-dose isoniazid-containing therapy for multidrug-resistant tuberculosis: a systematic review and meta-analysis
by: Ming Zhou, et al.
Published: (2024-01-01)

Drug susceptibilities of Mycobacterium tuberculosis against injectable second-line drugs from Pakistan: Analysis of multidrug-resistant and non-multidrug-resistant tuberculosis strains
by: Kauser Jabeen, et al.
Published: (2015-01-01)

Prevalence of and risk factors for multidrug-resistant tuberculosis in Iran and its neighboring countries: systematic review and meta-analysis
by: Worku Jimma, et al.

Trends in multidrug-resistant tuberculosis
by: I. M. F. Dias-Baptista, et al.
Published: (2008-01-01)

Factors affecting the treatment outcome of injection based shorter MDR-TB regimen at a referral centre in India
by: Kiran B, et al.
Published: (2022-10-01)

Frequency, management and impact of adverse events on treatment outcomes in patients with multidrug resistant tuberculosis in Balochistan, Pakistan
by: Sara Rafique, et al.
Published: (2024-12-01)

Whole-Genome Sequencing for Resistance Level Prediction in Multidrug-Resistant Tuberculosis
by: Jinli Li, et al.
Published: (2022-06-01)

Risk Factors for Multidrug-resistant Tuberculosis
by: Cleopas Martin Rumende
Published: (2018-04-01)

Drug resistance pattern of M. tuberculosis in category II treatment failure pulmonary tuberculosis patients
by: Fahmida Rahman, et al.
Published: (2013-01-01)

Multidrug and extensively drug-resistant tuberculosis management: Evidences and controversies
by: R Prasad
Published: (2012-01-01)

The use of BPaL containing regimen in the MDR/PreXDR TB treatments in Thailand
by: Piamlarp Sangsayunh, et al.
Published: (2024-02-01)

Hubungan Peran Keluarga dan Kepatuhan Pasien TB MDR di RSUD Dr. Soetomo Surabaya [The Role of Family in Improving Multidrug-Resistant Tuberculosis Patient Compliance]
by: Safira Nur Ainiyah, et al.
Published: (2019-01-01)

Factors associated with treatment success and death in cases with multidrug-resistant tuberculosis in Bulgaria, 2009–2010
by: Vladimir Milanov, et al.
Published: (2015-01-01)

Predictors of Multidrug-Resistant Tuberculosis (MDR-TB) in Sudan
by: Monadil H. Ali, et al.
Published: (2019-07-01)

Prevalence of resistance to second-line tuberculosis drug among multidrug-resistant tuberculosis patients in Viet Nam, 2011
by: Hoa Binh Nguyen, et al.
Published: (2016-06-01)

Treatment Outcomes and Associated Factors among Tuberculosis Patients from Selected Rural Eastern Cape Hospitals: An Ambidirectional Study
by: Lindiwe M. Faye, et al.
Published: (2023-06-01)

Accelerating development of new shorter TB treatment regimens in anticipation of a resurgence of multi-drug resistant TB due to the COVID-19 pandemic
by: Simon Tiberi, et al.
Published: (2021-12-01)

Clinical Features and Outcome of Multidrug-Resistant Osteoarticular Tuberculosis: A 12-Year Case Series from France
by: Isabelle Bonnet, et al.
Published: (2022-06-01)

Bedaquiline and Delamanid Combination Treatment of 5 Patients with Pulmonary Extensively Drug-Resistant Tuberculosis
by: Andrey Maryandyshev, et al.
Published: (2017-10-01)

Multidrug resistant tuberculosis versus non-tuberculous mycobacterial infections: a CT-scan challenge
by: Shahram Kahkouee, et al.
Published: (2013-04-01)

Multidrug resistant tuberculosis versus non-tuberculous mycobacterial infections: a CT-scan challenge
by: Shahram Kahkouee, et al.

Delamanid-containing regimens and multidrug-resistant tuberculosis: A systematic review and meta-analysis
by: Mohammad Javad Nasiri, et al.
Published: (2022-11-01)

Drug Resistance Characteristics of Mycobacterium tuberculosis Isolates From Patients With Tuberculosis to 12 Antituberculous Drugs in China
by: Xiaocui Wu, et al.
Published: (2019-11-01)

Multidrug- and Extensively Drug-Resistant Tuberculosis, Germany
by: Barbara Eker, et al.
Published: (2008-11-01)

Outbreak of Tuberculosis and Multidrug-Resistant Tuberculosis, Mbuji-Mayi Central Prison, Democratic Republic of the Congo
by: Michel Kaswa Kayomo, et al.
Published: (2018-11-01)

THE ROLE OF THE IMPLANTABLE PORT SYSTEM FOR THE CENTRAL VENOUS ACCESS IN TREATMENT OF PULMONARY TUBERCULOSIS WITH MULTIPLE AND EXTENSIVELY DRUG RESISTANCE (PRELIMINARY RESULTS)
by: О.R. RAZAKOV, et al.
Published: (2018-08-01)